https://www.selleckchem.com/pr....oducts/plerixafor-8h
These findings therefore suggest that DBH-AS1 can enhance glycolytic activity in melanoma cells, thereby disrupting melanoma progression via miR-223-3p/EGFR/AKT axis. As such this signaling axis may be a viable therapeutic target for melanoma treatment in human patients. These findings therefore suggest that DBH-AS1 can enhance glycolytic activity in melanoma cells, thereby disrupting melanoma progression via miR-223-3p/EGFR/AKT axis. As such this signaling axis may be a viable therapeutic target for melanoma treatment i
Like
Comment
Share
